- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| ME THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 25.10. | ME Therapeutics Holdings Inc: ME Therapeutics names Lalji chief business officer | 2 | Stockwatch | ||
| 25.10. | ME Therapeutics Holdings Inc. Appoints Chief Business Officer | 204 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - October 25, 2024) - ME Therapeutics Holdings Inc. (CSE:METX) (FSE:Q9T) ("ME Therapeutics" or the "Company"), a preclinical stage biotechnology company... ► Artikel lesen | |
| 22.10. | ME Therapeutics Holdings Inc: ME Therapeutics begins h1B11-12 cell line development | 1 | Stockwatch | ||
| 22.10. | ME Therapeutics Holdings Inc. Provides Research and Development Update and Corporate Update | 138 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - October 22, 2024) - ME Therapeutics Holdings Inc. (CSE: METX) (FSE: Q9T) ("ME Therapeutics" or the "Company"), a preclinical stage biotechnology company... ► Artikel lesen | |
| 18.09. | ME Therapeutics Holdings Inc: ME Therapeutics begins testing on mRNA formulations | 4 | Stockwatch | ||
| 18.09. | ME Therapeutics Holdings Inc.: ME Therapeutics Announces the Start of Testing of First mRNA Formulations from NanoVation Therapeutics Collaboration | 218 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - September 18, 2024) - ME Therapeutics Holdings Inc. (CSE: METX) (FSE: Q9T) ("ME Therapeutics" or the "Company"), a preclinical stage biotechnology company... ► Artikel lesen | |
| 08.07. | ME Therapeutics to collaborate with NanoVation Therapeutics | 1 | The Market Herald Canada | ||
| 08.07. | ME Therapeutics Holdings Inc.: ME Therapeutics Announces New Collaboration with NanoVation Therapeutics on Advanced Therapeutic mRNA Delivery to Myeloid Cells | 343 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - July 8, 2024) - ME Therapeutics Holdings Inc. (CSE: METX) (FSE: Q9T) ("ME Therapeutics" or the "Company"), a preclinical stage biotechnology company working... ► Artikel lesen | |
| 29.05. | ME Therapeutics Holdings Inc. Announces the Addition of Two New Clinical Consultants to Continue the Advancement of Our Lead Anti-G-CSF Antibody Candidate Towards a First-in-Human Clinical Trial | 167 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - May 29, 2024) - ME Therapeutics Holdings Inc. (CSE: METX) (FSE: Q9T) ("ME Therapeutics" or the "Company"), a preclinical stage biotechnology company working... ► Artikel lesen | |
| 17.05. | ME Therapeutics Holdings Inc.: ME Therapeutics to Present at Investor Clubhouse at the Canadian Open and Attend the 2024 BIO International Convention for Partnering Opportunities | 301 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - May 17, 2024) - ME Therapeutics Holdings Inc. (CSE: METX) (FSE: Q9T) ("ME Therapeutics" or the "Company"), a preclinical stage biotechnology company working... ► Artikel lesen | |
| 15.04. | ME Therapeutics Holdings Inc. Announces Ringing of CSE Opening Bell on April 17, 2024 | 235 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - April 15, 2024) - ME Therapeutics Holdings Inc. (CSE: METX) (FSE: Q9T), a preclinical stage biotechnology company working on novel cancer fighting drugs... ► Artikel lesen | |
| 26.03. | ME Therapeutics Holdings Inc. Announces Upcoming Participation in the 2024 Bloom Burton & Co Health Care Conference and Interview On CSE TV | 179 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - March 26, 2024) - ME Therapeutics Holdings Inc. (CSE: METX) (FSE: Q9T), a preclinical stage biotechnology company working on novel cancer fighting drugs... ► Artikel lesen | |
| 06.03. | ME Therapeutics Holdings Inc.: ME Therapeutics Announces Closing of Non-Brokered Private Placement | 226 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - March 6, 2024) - ME Therapeutics Holdings Inc. (CSE: METX) (FSE: Q9T) ("ME Therapeutics" or the "Company"), a preclinical stage biotechnology company... ► Artikel lesen | |
| 27.02. | ME Therapeutics Holdings Inc.: ME Therapeutics Announces Non-Brokered Private Placement and Provides Corporate Update | 526 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - February 27, 2024) - ME Therapeutics Holdings Inc. (CSE: METX) (FSE: Q9T) ("ME Therapeutics" or the "Company"), a preclinical stage biotechnology company... ► Artikel lesen | |
| 11.12.23 | ME Therapeutics Holdings Inc. Announces Listing on the Frankfurt Stock Exchange (FSE) and the Completion of Its Redesigned Website | 341 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - December 11, 2023) - ME Therapeutics Holdings Inc. (CSE: METX), a preclinical stage biotechnology company working on novel cancer fighting drugs in the... ► Artikel lesen | |
| 11.12.23 | XFRA NEW INSTRUMENTS AVAILABLE ON XETRA - 11.12.2023 | 1.157 | Xetra Newsboard | The following instruments on XETRA do have their first trading 11.12.2023 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 11.12.2023
Aktien
1 CA5527671054 Me Therapeutics Holdings... ► Artikel lesen |
16 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 41,475 | -0,48 % | QIAGEN N.V.: QIAGEN führt neuartige Tools zur Anpassung von digitalen PCR-Assays und NGS-Panels für die mikrobielle Analyse ein | QIAGEN führt das erste Design-Tool für individuell anpassbare digitale PCR-Assays im Markt ein, ausgestattet mit fortschrittlichen Design-Algorithmen für verschiedene mikrobielle Anwendungen und kundenspezifische... ► Artikel lesen | |
| EVOTEC | 8,585 | -3,86 % | wO Börsenlounge: Amazon | Hugo Boss | Evotec - nach Chipotle explodiert ein ganz neuer Wert! | Die Erfolgsgeschichte von Chipotle Mexican Grill ist zuletzt etwas ins Stocken geraten. Dafür springt ein neuer Wert in die Bresche. Seit Jahresanfang legt die Aktie um 200 Prozent zu und das dürfte... ► Artikel lesen | |
| JANUX THERAPEUTICS | 62,22 | +55,01 % | Pre-market Movers: Cheetah Net Supply Chain Service, NLS Pharmaceutics, PSQ Holdings, Janux Therapeutics, Coherus BioSciences | CANBERA (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 08.45 A.M. ET).In the Green Cheetah Net Supply Chain Service Inc. (CTNT) is up... ► Artikel lesen | |
| BIONTECH | 111,10 | -0,45 % | Evotec, Vidac Pharma, BioNTech - Krebsforschung: Die Goldgrube im Depot | Investitionen in Aktiengesellschaften, die im Bereich der Onkologieforschung tätig sind, bieten vielversprechende Renditechancen und langfristige Stabilität. Der Onkologiemarkt gehört zu den wachstumsstärksten... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 7,270 | -4,03 % | Recursion Pharmaceuticals, Inc.: Recursion announces first patient dosed in Phase 1/2 clinical study of REC-1245, a potential first-in-class, RBM39 degrader for Biomarker-Enriched Solid Tumors and Lymphoma | First program to result from end-to-end use of OS to identify a novel target and new chemical matter, which moved from target ID to IND enabling studies in under 18 months with ~200 compounds synthesizedREC-1245... ► Artikel lesen | |
| CITIUS ONCOLOGY | 1,410 | +38,24 % | Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (KEYTRUDA) and LYMPHIR in Cancer Patients ... | Study, in patients with solid tumors focusing on gynecological malignant tumors such as ovarian, endometrial, and cervical, nearing completion with three remaining subjects to be enrolled27%... ► Artikel lesen | |
| VERVE THERAPEUTICS | 7,330 | +2,73 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on November 29,... ► Artikel lesen | |
| ADMA BIOLOGICS | 19,760 | +0,36 % | Biotech Leader ADMA Hits New Buy Point After Recovering From Surprise Plunge | ||
| GUBRA | 91,20 | -6,56 % | AKTIONÄR-Depotwert Gubra: Nächstes Kaufsignal - neue Rekorde in Sicht | Die Bullen bleiben beim AKTIONÄR-Depotwert Gubra am Drücker. Zum Start in die neue Handelswoche strebt die Aktie des dänischen Wirkstoffforschers an der Heimatbörse in Kopenhagen auf ein neues Verlaufshoch... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 18,220 | -1,41 % | Summit Therapeutics Aktie: Verunsicherung steigt! | Summit Therapeutics, ein biopharmazeutisches Unternehmen, verzeichnet einen bemerkenswerten Aufschwung an der Börse. Die Aktie schloss am 9. November 2024 bei 21,41 USD, was einem Anstieg von 1,47%... ► Artikel lesen | |
| SENTI BIOSCIENCES | 7,370 | -27,10 % | Senti Biosciences, Inc.: Senti Bio Announces Positive Initial Clinical Data in Phase 1 Clinical Trial of SENTI-202, a Logic Gated, Selective CD33/FLT3-Targeting CAR-NK Cell Therapy for the Treatment of Relapsed/Refractory ... | - 2 of 3 patients achieved MRD negative CR in the first dose level evaluated in the trial with a generally well-tolerated preliminary safety profile - - Dose escalation is continuing with additional... ► Artikel lesen | |
| CABALETTA BIO | 3,675 | -10,69 % | Cabaletta Bio Reports Second Quarter 2024 Financial Results and Provides Business Update | - Nine patients enrolled as of August 5, 2024 across the RESET clinical development program, including four since EULAR in June, with 22 U.S. clinical sites now enrolling - - Additional clinical data... ► Artikel lesen | |
| COHERUS | 1,789 | +37,56 % | Coherus, sharpening immuno-oncology focus, sells another biosimilar for over $500M | ||
| BB BIOTECH | 40,350 | -0,12 % | BB Biotech Aktie: Klare Gewinne sichtbar! | ||
| AMGEN | 265,55 | +0,26 % | Opening Bell: Bitcoin, Amgen, Eli Lilly, The GEO Group, Amazon, Ebay, Walmart, Archer Aviation | Der Start in die neue Woche kann sich für die Wall Street sehen lassen. Der Dow Jones und der S&P 500 erreichten gestern neue Bestmarken. Heute deutet sich bei den großen Indizes ein verhaltener Start... ► Artikel lesen |
ME THERAPEUTICS HOLDINGS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 1,830 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ME THERAPEUTICS HOLDINGS INC finden Sie auf Wallstreet Online.
